Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 5 mg - 52 EUR
  • 25 mg - 208 EUR
  • 100 mg - 624 EUR

Olaparib

Olaparib is a single digit nanomolar inhibitor of poly(adenosine diphosphate-ribose) polymerase (PARP), an enzyme that is involved in DNA damage repair. It exhibits IC50 values of 5 and 1 nM for PARP-1 and PARP-2, respectively, and is being developed as a drug for BRCA1- and BRCA2-defective cancers.

catalogue number: O057
synonyms: AZD2281, KU-0059436
CAS: 763113-22-0
MW: 434.46 g/mol

References
J Med Chem. 2008 Oct 23;51(20):6581-91. PMID: 18800822
Blood. 2010 Nov 25;116(22):4578-87. PMID: 20739657
Mol Cancer Ther. 2011 Oct;10(10):1949-58. PMID: 21825006

Prices
  • 5 mg - 41 EUR
  • 25 mg - 164 EUR
  • 100 mg - 492 EUR

Olomoucine

Olomoucine was one of the first selective inhibitors of cyclin-dependent kinases (CDKs) to be discovered. It competes with ATP for binding to the kinase active site, as demonstrated by the structure of a co-crystal with human CDK2. It was discovered by screening a library of 2,6,9-trisubstituted purines. Studies on olomoucine analogues resulted in the identification of the much more potent inhibitor roscovitine.

catalogue number: O058
synonyms: 2-(2-hydroxyethylamino)-6- benzylamino-9-methylpurine
CAS: 101622-51-9
MW: 298.34 g/mol

References
Eur J Biochem. 1994 Sep 1;224(2):771-86. PMID: 7925396
Biol Cell. 1995;83(2-3):105-20. PMID: 7549905
Proteins. 1995 Aug;22(4):378-91. PMID: 7479711
Crystal structure of human CDK2 in complex with olomoucine PDB: 1W0X

Prices
  • 5 mg - 98 EUR
  • 25 mg - 392 EUR
  • 100 mg - 1176 EUR

Olomoucine II

Olomoucine II is potent inhibitor of several cyclin-dependent kinases (CDKs). It is an ATP-competitor that binds to the active site of CDK2, as demonstrated by the analysis of co-crystal structures. In addition to its inhibition of the main cell cycle-regulating kinase CDK2, olomoucine II also binds to CDK7 and CDK9, which play important roles in regulating RNA transcription. It has been shown to have in vitro anticancer activity against a panel of tumor cell lines.

catalogue number: O059
synonyms:
CAS: 500735-47-7
MW: 370.45 g/mol

References
Bioorg Med Chem Lett. 2002 Nov 18;12(22):3283-6. PMID: 12392733
Cell Mol Life Sci. 2005 Aug;62(15):1763-71. PMID: 16003486
Crystal structure of human CDK2 in complex with olomoucine II PDB: 2A0C

Prices
  • 25 mg - 59 EUR
  • 100 mg - 148 EUR
  • 250 mg - 296 EUR

Oxaliplatin

Oxaliplatin exhibits clinical acitivity against a wide range of tumours. The retention of the bulky 1,2-diaminocyclohexane ring by activated oxaliplatin is thought to result in the formation of platinum-DNA adducts, which appear to be more effective at blocking DNA replication and more cytotoxic than adducts formed from cisplatin.

catalogue number: O128
synonyms: Eloxatin
CAS: 61825-94-3
MW: 397.29 g/mol

References
Semin Oncol. 1998 Apr;25(2 Suppl 5):4-12. PMID: 9609103
Crit Rev Oncol Hematol. 2000 Aug;35(2):75-93. PMID: 10936465